Wegener's granulomatosis in pediatric patients;Wegener-granulomatose bei pädiatrischen patienten

Klinische Padiatrie

Volumn 219, Issue 6, 2007, Pages 348-354

  Fiebig, B ^a,c   Hedrich, C M ^a   Heubner, C ^b   Gahr, M ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b Weißeritztal Kliniken   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Childhood; Vasculitis; Vasculitis treatment; Wegener's granulomatosis

Indexed keywords

AZATHIOPRINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PLACEBO; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR;

ALLERGY; ARTICLE; CHRONIC DISEASE; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG PULSE THERAPY; EARLY INTERVENTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY; KIDNEY FAILURE; LONG TERM CARE; LOWER RESPIRATORY TRACT; MICROSCOPIC POLYANGIITIS; PATHOPHYSIOLOGY; PEDIATRICS; PROGNOSIS; RARE DISEASE; RELAPSE; RESPIRATORY SYSTEM; UPPER RESPIRATORY TRACT; VASCULITIS; WEGENER GRANULOMATOSIS;

ADOLESCENT; ADRENAL CORTEX HORMONES; AGE FACTORS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INFANT, NEWBORN; MAGNETIC RESONANCE IMAGING; MALE; METHOTREXATE; PROGNOSIS; RADIOGRAPHY, THORACIC; RECURRENCE; TOMOGRAPHY, X-RAY COMPUTED; WEGENER GRANULOMATOSIS;

EID: 36949008730     PISSN: 03008630     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-971047     Document Type: Article

References (49)

1. Belostotsky VM, Shah V, Dillon MJ. Clinical features in 17 paediatric patients with Wegener granulomatosis. Pediatr Nephrol 2002; 17: 754-761
2. Boomsma MM et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmatic antibody levels: a prospective study. Arthritis Rheum 2000; 43: 2025-2033
3. Booth A, Harper L, Hammad T, Bacon P et al. Prospektive study of TNFα blockade with Infliximab in antineutrophil cytoplasmatic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004; 15: 717-721
4. Cohen Tervaert JW, Woude FJ van der, Fauci AS, Ambrus JL, Velosa J, Keane WF, Meijer S, Giessen M van der, Hem GK van der. The Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med 1989; 149: 2461-2465
5. De Groot K, Reinhold-Keller E, Tatsis E, Paulsen J, Heller M, Nölle B, Gross WL. Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis. Methotrexate versus trimethoprim/sulphamethoxazole. Arthritis Rheum 1996; 39: 2052-2061
6. Dijstelbloem HM, Scheepers RH, Oost WW et al. Fc gamma receptor polymorphisms in Wegener's granulomatosis: risk faktor for disease relapse. Arthritis Rheum 1999; 42: 1823-1827
7. Elkon KB, Sutherland DC, Rees AJ, Hughes GR, Batchelor JR. HLA antigen frequencies in systemic vasculitis: increase in HLA-DR2 in Wegener's granulomatosis. Arthritis Rheum 1983; 26: 102-105
8. Fauci AS, Katz P, Haynes BF, Wolff SM. Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med 1979; 301: 235-238
9. Frosch M, Foell D. Wegener granulomatosis in childhood and adolescence. Eur J Pediatr 2004; 163: 425-434
10. Guillevan L, Cordier JF, Lhote F, Cohen P et al. A prospective, multicenter, randomised trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997; 40: 2187-2198
11. Gordon M, Luqmani RA, Adu D et al. Relapses in patients with a systemic vasculitis. QJ Med 1993; 86: 779-789
12. Haubitz M, Schellong S, Göbel U, Schurek HJ, Schaumann D, Koch KM, Brunkhorst R. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmatic antibody-associated vasculitis and renal invovement. A prospective, randomised study. Arthritis Rheum 1998; 41: 1835-1844
13. Hoffman GS. Immunosuppressive therapy is always required for the treatment of limited Wegener's granulomatosis. Sarcoidosis Vasc Diffuse Lung Dis 1996; 13: 249-252
14. Hoffman GS. Wegener's granulomatosis: the path traveled since 1931. Medicin (Baltimore) 1994; 73: 325-329
15. Hoffman GS, Kerr GS, Leavitt RY et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 488-498
16. Hoffman GS, Leavitt RY, Ken GS et al. Treatment of Wegener's Granulomatosis with glucocorticoids and Methotrexate. Arthritis Rheum 1992; 35: 1322-1329
17. Hollander D, Manning RT. The use of alkylating agents in the treatment of Wegener's granulomatosis. Ann Intern Med 1967; 67: 393-398
18. Joy SM, Hogan LS, Jennete C, Falk JR, Nachman HP. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transplant 2005; 20: 2725-2732
19. Katz P, Alling DW, Haynes BF, Fauci AS. Association of Wegener's granulomatosis with HLA-B8. Clin Immunol Immunpathol 1979; 14: 268-270
20. Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for Refractory Wegener's granulomatosis: Report of a prospective, open-label pilot trial. AJRCCM 2006; 173: 180-187
21. Kerr GS, Fleisher TA, Hallahan CW, Leavitt RY, Fauci AS, Hoffman GS. Limited prognostic value of changes in antineutrophil cytoplasmatic antibody titer in patients with Wegener's granulomatosis. Arthritis Rheum 1993; 36: 365-371
22. Koldingsnes W, Nossent H. Predictors of survival and organ damage in Wegener's granulomatosis. Rheumatology (Oxford) 2002; 41: 572-581
23. Langford CA, Hoffman GS. Wegener's granulomatosis. Thorax 1999; 54: 629-637
24. Langford CA, Talar-Williams C, Barron KS, Sneller MC. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 2003; 114: 463-469
25. Langford CA, Talar-Williams C, Barron KS, Sneller MC. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 1999; 42: 2666-2673
26. Lindsley CD, Laxer RM. Granulomatous vasculitis. Giant cell arteriitis and sarcoidosis In: Cassidy JT, Petty RE, Laxer RM, Lindsley CB (Hrsg) Textbook of Pediatric Rheumatology. Elsevier Saunders, Philadelphia 2005; S 539-S 560
27. Nowack R, Göbel U, Klooker P, Hergesell O, Andrassy K, Woude FJ van der. Mycophenolate Mofetil for Maintenance Therapy of Wegener's Granulomatosis and Microscopic Polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol 1999; 10: 1965-1971
28. Ozen S, Ruperto N, Dillon MJ, Bagga A, Barron K, Davin JC, Kawasaki T, Lindsley C, Petty RE, Prieur AM, Ravelli A, Woo P. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Annals of Rheumatology Dis. 2006; 65: 936-941
29. Papiha SS, Murty GE, Ad'Hia A, Mains BT, Venning M. Association of Wegener's granulomatosis with HLA antigens and other genetic markers. Ann Rheum Dis 1992; 51: 246-248
30. Raynold JP, Bloch DA, Fries JF. Seasonal variation in the onset of Wegener's granulomatosis, polyarteritis nodosa and giant cell arteritis. J Rheumatol 1993; 20: 1524-1526
31. Reinhold-Keller E, Fink C, Herlyn K, Gross WL, Groot K De. High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis and Rheumatism 2002; 47: 326-332
32. Rottem M, Fauci AS, Hallahan CW et al. Wegener granulomatosis in children and adolescents: clinical presentation and outcome. J Pediatr 1993; 122: 26-31
33. Ruder H, Rieger CHL. Wegener Granulomatose In: Wahn V (Hrsg). Rheumatische Erkrankungen im Kindes- und Jugendalter. Hans Marseille Verlag, München 2001; 346-355
34. Ruemmele FM, Targan SR, Levy G, Dubinsky M, Braun J, Seidman EG. Diagnostic Accurance of Serological Assays in Pediatric Inflammatory Bowel Disease. Gastroenterology 1998; 115: 822-829
35. Sanders JS, Stassen PM, Rossum AP van, Kallenberg CG, Stegeman CA. Risk factors for relapse in anti-neutrophil cytoplasmatic antibody (ANCA)-associated vasculitis: tools for treatment decisions? Clin Exp Rheumatol 2004; 22: 94-101
36. Sanaf P, Sneller MC. Pathogenesis of Wegener's granulomatosis: current concepts. Expert Rev Mol Med May 13 2005; 7: 1-19
37. Segelmark M, Elzouki AN, Wieslander J, Eriksson S. The PiZ gene in alpha 1-antitrypsin as a determinant of outcome in PR3-ANCA-positive vasculitis. Kidney Int 1995; 48: 844-850
38. Slater CA, Liang MH, MacCune JW, Christman GM, Laufer MR. Preserving ovarian function in patients receiving cyclophosphamide. Lupus 1999; 8: 3-10
39. Sneller MC, Fauci AS. Pathogenesis of vasculitis syndromes. Med Clin North AM 1997; 81: 221-242
40. Sneller MC, Hoffman GS, Talar-Williams C, Kerr GS, Hallahan CW, Fauci AS. An analysis of forty-two Wegener'sgranulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995; 38: 608-613
41. Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D. Long-term observation of patients with anti-neutrophil cytoplasmatic antibody-associated vasculitis treated with rituximab. Rheumatology 2006; 1-5 [Epub ahead of print]
42. Stegeman CA, Travaert JW, Sluiter WJ et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener's granulomatosis. Ann Intern Med 1994; 120: 12-17
43. Stegmayr BG, Gothefors L, Malmer B, Müller Wiefel DE, Nilsson K, Sundelin B. Wegener granulomatosis in children and young adults. Pediatr Nephrol 2000; 14: 208-213
44. Stone JH, Uhlfelder ML, Hellmann DB et al. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six month open-label trial to evaluate safety. Arthritis Rheum 2001; 44: 1149-1154
45. Stone JH, Holbrook JT, Marriott MA, Tibbs AK, Sejismundo LP, Min YI, Specks U, Merkel PA, Spiera R, Davis JC, St. Clair EW, MacCune WJ, Ytterberg SR, Allen NB, Hoffman GS. Solid Malignancies among Patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis and Rheumatism 2006; 54: 1608-1618
46. Geld YM van der, Limburg PC, Kallenberg CG. Proteinase 3, Wegener's autoantigen: from gene to antigen. J Leukoc Biol 2001; 69: 177-190
47. Walton EW. Giant cell granuloma of the respiratory tract (Wegener's granulomatosis). BMJ 1958; 2: 265-270
48. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352: 351-361
49. Weiner SR, Paulus HE. Treatment of Wegener's granulomatosis. Semin Respir Med 1989; 10: 156-161